利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.021 秒)

    ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES
    5.
    发明申请
    ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES 审中-公开

    公开(公告)号：US20130183310A1

    公开(公告)日：2013-07-18

    申请号：US13785643

    申请日：2013-03-05

    申请人： Peter Carmeliet ,  Desire Collen ,  Sandro De Falco ,  Ruvo Menotti

    发明人： Peter Carmeliet ,  Desire Collen ,  Sandro De Falco ,  Ruvo Menotti

    IPC分类号： C07K16/22

    CPC分类号： C07K16/22 ,  A61K38/07 ,  A61K39/3955 ,  A61K2039/505 ,  C07K1/047 ,  G01N2333/71

    摘要： The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.

    Use of VEGF and homologues to treat neuron disorders
    7.
    发明申请
    Use of VEGF and homologues to treat neuron disorders 失效
    使用VEGF和同系物治疗神经元疾病

    公开(公告)号：US20070249539A1

    公开(公告)日：2007-10-25

    申请号：US11810017

    申请日：2007-06-04

    申请人： Peter Carmeliet ,  Desire Collen ,  Bert Oosthuyse

    发明人： Peter Carmeliet ,  Desire Collen ,  Bert Oosthuyse

    IPC分类号： A61K38/18 ,  A61P25/16 ,  A61P25/28

    CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0356 ,  A61K38/1866 ,  A61K48/00 ,  C07K14/52 ,  C12N15/8509 ,  C12N2800/30 ,  C12N2830/002 ,  C12N2830/85

    摘要： The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.

    摘要翻译： 本发明涉及与神经元疾病相关的神经和生理功能障碍。 特别地，本发明涉及血管内皮生长因子（VEGF）和同系物参与运动神经元疾病的病因学。 本发明还涉及在VEGF启动子的缺氧应答元件（HRE）中具有纯合缺失的新型突变转基因小鼠（VEGF m / m），其改变VEGF的缺氧上调。 这些小鼠由于进行性脊髓运动神经元变性而遭受严重的成人发作肌肉无力，其使人想起肌萎缩性侧索硬化（ALS） - 一种具有未知病因的致命性疾病。 此外，这些小鼠的神经病变不是由血管缺陷引起的，而是由于VEGF介导的运动神经元的生存信号。 本发明特别涉及通过与神经蛋白-1结合刺激运动神经元的存活的异构体165，该神经蛋白-1是已知与轴突回缩和神经元死亡有关的信号素-3A的已知结合受体，以及 VEGF受体-2。 因此，本发明涉及VEGF，特别是VEGF 165用于治疗神经元病症的用途，此外还涉及VEGF启动子中用于诊断后一种疾病的多态性的用途。

    Composition and method for modulating vasculogenesis for angiogenesis
    9.
    发明申请
    Composition and method for modulating vasculogenesis for angiogenesis 审中-公开
    用于血管生成调节血管生成的组合物和方法

    公开(公告)号：US20070172423A1

    公开(公告)日：2007-07-26

    申请号：US11605607

    申请日：2006-11-29

    申请人： Xuri Li ,  Ulf Eriksson ,  Peter Carmeliet ,  Desire Collen

    发明人： Xuri Li ,  Ulf Eriksson ,  Peter Carmeliet ,  Desire Collen

    IPC分类号： A61K51/00 ,  A61K39/395 ,  C07K16/30 ,  C07K16/46

    CPC分类号： A61K51/1018 ,  A61K38/00 ,  C07K14/49 ,  C07K16/22 ,  C12N2799/026

    摘要： A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

    摘要翻译： 使用PDGF-C的核心结构域蛋白，PDGF / VEGF生长因子家族的新成员或同型二聚体或异二聚体调节血管发生或动脉发生或血管发生，特别是用于治疗心脏和肢体缺血的方法，所述方法包括核心 域。 还公开了包含核心蛋白质，编码蛋白质的核苷酸序列及其在医学和诊断应用中的用途的药物组合物。